Provided by Tiger Trade Technology Pte. Ltd.

HBM HOLDINGS-B

14.190
-0.250-1.73%
Volume:8.78M
Turnover:125.24M
Market Cap:12.33B
PE:129
High:14.740
Open:14.440
Low:13.980
Close:14.440
52wk High:17.070
52wk Low:9.460
Shares:869.00M
HK Float Shares:869.00M
Volume Ratio:0.52
T/O Rate:1.01%
Dividend:- -
Dividend Rate:- -
EPS(LYR):0.110
ROE:23.97%
ROA:10.88%
PB:3.76
PE(LYR):129.00
PS:8.78

Loading ...

Hbm - Co and Biomap to Jointly Initiate Megastream Techbio

THOMSON REUTERS
·
Jun 15

Hbm - Co and Biomap Enter Global Strategic Partnership for AI-Driven Biologics

THOMSON REUTERS
·
Jun 15

HBM Holdings-B Prevails in Patent Infringement Case Against Amgen, Awarded Approximately $20.2 Million with Potential for Triple Damages

Stock News
·
Jun 15

Harbour Biomed Secures Landmark Victory in U.S. Patent Infringement Case Against Amgen, Reshaping the Global Antibody Patent Landscape

THOMSON REUTERS
·
Jun 15

HBM Holdings wins US patent jury verdict against Amgen, awarded USD 20.2 million damages

Reuters
·
Jun 15

Hbm - Jury Returns Verdict in Favor of Harbour Antibodies Against Amgen in U.S. Patent Case

THOMSON REUTERS
·
Jun 15

Hbm Holdings - Jury Verdict in U.S. Patent Infringement Litigation

THOMSON REUTERS
·
Jun 15

Hbm Holdings - IF Such Enhanced Damages Are Granted in Full, Award Could Increase to up to Approximately US$60.6 Mln

THOMSON REUTERS
·
Jun 15

Hbm Holdings - Harbour Antibodies Is Entitled to Damages of US$20.2 Mln Being Full Amount Requested at Trial

THOMSON REUTERS
·
Jun 15

HBM Holdings (SEHK:2142) Stock Valuation After New IND Milestone For Cancer Antibody HBM7004

Simply Wall St.
·
Jun 13

Amgen owes $20.2 million in antibody patent lawsuit, US jury says

Reuters
·
Jun 13

Harbour BioMed appoints Sana Biotechnology CSO Dhavalkumar Patel as scientific advisor

Reuters
·
Jun 12

Press Release: Harbour BioMed Appoints Dr. Dhavalkumar Patel as Scientific Advisor

Dow Jones
·
Jun 12

Harbour BioMed appoints Luisa Salter-Cid as scientific advisor

Reuters
·
Jun 11

BUZZ-China's HBM climbs on regulator's nod on application of new cancer drug

Reuters
·
Jun 10

Hong Kong Stocks Show Movement: Super-Long-Acting Anti-TSLP Antibody Phase II Trial Completes First Dosing; HBM Holdings-B and SKB BIO Both Surge Over 5% During Session

Stock News
·
Jun 10

HBM Holdings Partner Doses First Patient in SKB378 COPD Study

MT Newswires Live
·
Jun 10

HBM Holdings Secures NMPA IND Acceptance for Bispecific Antibody HBM7004 in Advanced Solid Tumors

Bulletin Express
·
Jun 10

HBM HOLDINGS-B Receives NMPA Acceptance for Investigational New Drug Application of HBM7004

Stock News
·
Jun 10

HBM Holdings says China NMPA accepts IND for HBM7004 in advanced solid tumors

Reuters
·
Jun 10